Thermo Fisher Scientific Inc. $TMO Shares Sold by Keybank National Association OH

by · The Markets Daily

Keybank National Association OH cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 4.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 279,710 shares of the medical research company’s stock after selling 12,685 shares during the quarter. Keybank National Association OH’s holdings in Thermo Fisher Scientific were worth $137,486,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in TMO. Heritage Investors Management Corp grew its position in Thermo Fisher Scientific by 1.0% during the first quarter. Heritage Investors Management Corp now owns 56,987 shares of the medical research company’s stock valued at $28,011,000 after buying an additional 554 shares during the period. KPP Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 1.8% during the 1st quarter. KPP Advisory Services LLC now owns 4,340 shares of the medical research company’s stock valued at $2,133,000 after acquiring an additional 77 shares during the period. Eagle Bluffs Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 3.4% in the 1st quarter. Eagle Bluffs Wealth Management LLC now owns 4,416 shares of the medical research company’s stock worth $2,173,000 after purchasing an additional 147 shares during the period. Reliant Investment Management LLC grew its holdings in Thermo Fisher Scientific by 1.1% in the first quarter. Reliant Investment Management LLC now owns 12,095 shares of the medical research company’s stock valued at $5,945,000 after purchasing an additional 135 shares during the period. Finally, Twin City Private Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $273,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 1.8%

TMO opened at $522.38 on Friday. The firm has a market capitalization of $194.13 billion, a price-to-earnings ratio of 28.72, a price-to-earnings-growth ratio of 2.27 and a beta of 0.87. The company’s 50 day simple moving average is $473.02 and its two-hundred day simple moving average is $518.12. Thermo Fisher Scientific Inc. has a 1-year low of $403.36 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the business earned $5.15 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target for the company. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price target for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus lowered their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Finally, Barclays decreased their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $605.09.

Get Our Latest Stock Report on Thermo Fisher Scientific

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).